iBioModulator Portfolio & Product Pipeline From Pulmonary Fibrosis, SSc Drug Developer iBio Gains Key Patent
Idiopathic Pulmonary Fibrosis, News
iBio, Inc recently announced that the company was approved for a new U.S. patent entitled “Yersinia pests Antigens, Vaccine Compositions and Related Methods.” The scope of this new patent includes plague antigens combined with the ... Read more